• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

AAP guidelines for pneumococcal vaccination in high-risk groups released

byNeha JoshiandLeah Carr, MD
November 24, 2014
in Chronic Disease, Infectious Disease, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The AAP continues to recommend PPSV23 vaccination in children at high risk for invasive pneumococcal disease (IPD).

2. New guidelines suggest that children ages 6 to 18 with high risk for IPD additionally receive PCV13 if not previously immunized with this conjugate vaccine during early childhood.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Despite reduction in Streptococcal pneumoniae disease burden with the routine use of pneumococcal conjugate vaccines, IPD still continues to cause significant morbidity and mortality in the pediatric population. This AAP Policy Statement serves to update guidelines for pneumococcal vaccination in children ages 6 through 18 with conditions that place them at greater risk for IPD. Such conditions include immunocompromised states (HIV, congenital immunodeficiency, etc), asplenia, sickle cell disease, cerebrospinal fluid leaks, or cochlear implants. Children with chronic disease (lung, heart, diabetes, etc) are additionally at higher risk of IPD. Vaccinations included in these guidelines are the 13-valent PCV13 (4 doses before 18 months currently recommended in all children) and the extended 23-valent PPSV23 (currently only recommended in high risk pediatric groups). For children ages 6 through 18 years, the AAP continues to recommend 1 dose of PPSV23 to children with cerebrospinal fluid leaks or cochlear implants and 2 doses of PPSV23 given 5 years apart to children with immunocompromised states, asplenia, or sickle cell disease. The new aspect of these updated guidelines suggests that children receiving PPSV23 who have not previously received PCV13 during early childhood should now receive a single PCV13 dose. Immunocompetent children with chronic disease (chronic lung disease, heart disease, diabetes, etc) may additionally be considered for the PCV13 vaccine if not previously vaccinated. This recommendation comes from evidence that such administration is safe and that it will provide broader protection for high risk children against IPD.

Click to read the policy statement in Pediatrics

Relevant Reading: Decline in Invasive Pneumococcal Disease after the Introduction of Protein-Polysaccharide Conjugate Vaccine

RELATED REPORTS

2 Minute Medicine Rewind July 14, 2025

Mazdutide significantly reduces weight in adults with overweight or obesity

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

More from this author: Majority of obese tenth-graders already obese by fifth grade, New AAP guidelines against albuterol for bronchiolitis, Continuous albuterol thought to be safe in floor setting, Study suggests twice as many antimicrobials prescribed than needed, MMR vaccination intentions higher with direct benefit education

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: chronic diseasePneumococcalvaccination
Previous Post

Prenatal lead exposure and calcium intake linked to postnatal growth

Next Post

2 Minute Medicine Rewind November 17 – November 23, 2014

RelatedReports

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Weekly Rewinds

2 Minute Medicine Rewind July 14, 2025

July 14, 2025
Increasing maternal BMI linked to higher risk of cerebral palsy
Cardiology

Mazdutide significantly reduces weight in adults with overweight or obesity

July 11, 2025
Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
Chronic Disease

Weighted vests and resistance training confer similar outcomes for bone density in the elderly

June 27, 2025
Next Post
Dexamethasone shows comparable efficacy to prednisone/prednisolone in pediatric asthma

2 Minute Medicine Rewind November 17 – November 23, 2014

Basic life support associated with greater survival in cardiac arrest

Basic life support associated with greater survival in cardiac arrest

Long-term dual antiplatelet therapy does not increase mortality risk

Long-term dual antiplatelet therapy does not increase mortality risk

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • St. Louis hospital-based violence intervention program did not significantly affect reinjury outcomes
  • Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
  • Vaporized nicotine products may be effective for smoking cessation among people with social disadvantage
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.